-47%

est. 2Y upside i

Healthcare

Rank

#3925

Sector

Healthcare Technology

Est. Liquidity

~3Y

Data Quality

Data: Medium

Athenahealth, a private company acquired for $17.0B in 2022, operates in a large but highly competitive healthcare technology market.

Last updated: March 10, 2026

Bull (15%)+75%

Athenahealth successfully leverages its recent AI initiatives and strategic partnerships (e.g., CenterWell, Nabla, b.well) to significantly expand its market penetration and enhance its athenaOne platform's capabilities. This innovation, coupled with strong execution in the ambulatory care segment, drives revenue growth above 20% YoY, leading to a successful IPO or secondary sale by its PE owners at a valuation of approximately $29.75B (1.75x current valuation) within 2-3 years.

Base (45%)+10%

Athenahealth maintains its strong position in the small to medium-sized physician practice market, continuing to grow revenue at a moderate pace (~15% YoY) by enhancing its core EHR and RCM offerings. While fending off competitive pressures from incumbents, the company achieves incremental operational efficiencies. A liquidity event (IPO or secondary sale) occurs at a valuation of approximately $18.7B (1.1x current valuation), reflecting steady performance but limited multiple expansion due to market maturity and competitive landscape.

Bear (40%)-40%

Dominant incumbents like Epic and Oracle Health aggressively expand into Athenahealth's core ambulatory market, leveraging their vast resources and existing hospital relationships. This intensified competition, combined with potential regulatory headwinds or slower-than-expected adoption of new AI features, stifles Athenahealth's growth. A liquidity event occurs at a down-round valuation of approximately $10.2B (0.6x current valuation), significantly eroding common stock value given the substantial liquidation preferences.

Est. time to liquidity~2.5 years

Preference Stack Risk

severe

Funding Intensity

42%

Investors acquired Athenahealth for $17.0B, having invested $7.1B in total funding, implying a significant portion of the acquisition price would go to preferred shareholders/debt holders before common equity holders in a downside scenario.

Dilution Risk

moderate

As a private company owned by private equity, future dilution from venture funding rounds is less likely, but new equity grants or recapitalizations by the PE owners could impact existing employee equity.

Secondary Liquidity

limited

As a privately held company under private equity ownership, there is typically no active secondary market for employee equity, though occasional tender offers might occur.

Questions to Ask at the Interview

Strategic questions based on Athena's data — designed to show you've done your homework.

  • 1

    “How does Athenahealth plan to effectively differentiate and compete against the expanding cloud offerings and market dominance of incumbents like Epic and Oracle Health, particularly in the ambulatory care segment?”

  • 2

    “Given the hybrid revenue model and recent AI enhancements, what is Athenahealth's strategy for accelerating revenue growth beyond the current ~16% YoY weighted growth, and how do you foresee the AI features impacting the performance-based RCM fees?”

  • 3

    “As a private equity-owned company, what is the anticipated timeline and strategic path for a future liquidity event (e.g., IPO or secondary sale), and how is the company ensuring that employee equity grants will yield meaningful returns given the $7.1B in total funding on a $17.0B valuation?”

Community

Valuation Sentiment

Our model estimates -47% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.